Citations 1

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

NEJM Evidence | June 6, 2022 | Volume: 1 | Issue: 8 | Pages: No page available

10.1056/evidoa2100070 | PMID 38319892